FAM
CRSP icon

Fred Alger Management’s CRISPR Therapeutics CRSP Stock Holding History

Fred Alger Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-4,573
Closed -$299K – 526
2022
Q3 		$299K Buy
+4,573
New +$331K ﹤0.01% 418
2020
Q1 		– Sell
-13,000
Closed -$792K – 555
2019
Q4 		$792K Buy
+13,000
New +$710K ﹤0.01% 360
2018
Q3 		– Sell
-6,000
Closed -$353K – 552
2018
Q2 		$353K Buy
+6,000
New +$342K ﹤0.01% 371

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
AWA
Arete Wealth Advisors Chicago, Illinois $1.33B AUM 25.12% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Fred Alger Management's CRSP Position: Q4 2022 in Review

Fred Alger Management sold out of CRISPR Therapeutics (CRSP) in Q4 2022, closing a stake of 4,573 shares — an estimated $299K sold.

Fred Alger Management first reported a position in CRSP in Q2 2018 and held it in 3 quarters. The position peaked at $792K in Q4 2019. 398 funds tracked by Wall St. Rank hold CRSP as of Q4 2022.

  • Fred Alger Management reported no remaining CRISPR Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Fred Alger Management sold 4,573 CRISPR Therapeutics shares in Q4 2022, an estimated $299K.
  • Fred Alger Management first reported a position in CRISPR Therapeutics in Q2 2018 and held it in 3 quarters.
  • Fred Alger Management's CRISPR Therapeutics position peaked at $792K in Q4 2019.
  • 398 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2022.

Based on Fred Alger Management's 13F filing for Q4 2022, filed 14 Feb 2023.